Non-alcoholic fatty liver disease following liver transplantation: a clinical review.

Abstract

Non-alcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation (LT) in the United States. While post-transplantation outcomes are similar to other indications for transplant, recent evidence has suggested that reduction in risk factors for post-transplant metabolic syndrome may impose a significant survival benefit in this patient population. Cardiovascular mortality is the leading cause of death following transplantation for NASH. While pre-transplant pharmacologic and surgical approaches have been utilized to reduce cardiovascular risk factors following transplantation, the effectiveness of these treatment approaches in the post-transplant setting is poorly defined. Studies are urgently needed in the treatment of this rapidly growing population.

• Authors: Jonathan Merola, AnnMarie Liapakis, David C Mulligan, Peter S Yoo
• Journal: Clinical transplantation (Clin Transplant) Vol. 29 Issue 9 Pg. 728-37 (Sep 2015) ISSN: 1399-0012 [Electronic] Denmark
• PMID: 26147308 (Publication Type: Journal Article, Review)
• Copyright: © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Topics

• Cardiovascular Diseases (etiology, prevention & control)
• Combined Modality Therapy
• Humans
• Liver Transplantation
• Metabolic Syndrome (etiology, prevention & control)
• Non-alcoholic Fatty Liver Disease (diagnosis, etiology, surgery, therapy)
• Postoperative Complications (diagnosis, etiology, prevention & control, therapy)
• Risk Factors
• Treatment Outcome